BROVANA® (arformoterol tartrate):
No tolerance over 6 months as measured by mean change in FEV1 AUC0-61,2
Mean change in FEV1 AUC0-6 from baseline1,2
Double-blind, double-dummy, multicenter, randomized, active-controlled, parallel-group safety study that evaluated the long-term safety of nebulized BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg twice daily in 149 patients with COPD over 6 months. Formoterol was an active comparator.1,2
- The primary endpoint of this study was to evaluate the overall occurrence of adverse events including COPD exacerbations2
- While primarily designed to assess safety, secondary endpoints included FEV1 change and percent change in FEV1 from study baseline and visit predose1,2
BROVANA® (arformoterol tartrate) Inhalation Solution is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.
BROVANA® (arformoterol tartrate) Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.
BROVANA® (arformoterol tartrate) Inhalation Solution should not be used in conjunction with other inhaled, long-acting beta2-agonists.